SCHEMBL3569615

SCHEMBL3569615

O=C(/C=C/c1cccc(F)c1F)/C=C/c1cccc(F)c1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.56
NFE2L2 Q16236 4/20 0.52
NFKB1 P19838 2/20 0.52
JUN P05412 1/20 0.52
HSD11B1 P28845 2/20 0.50
TFEB P19484 1/20 0.46
CES2 O00748 2/20 0.45
CES1 P23141 2/20 0.45
BCHE P06276 1/20 0.45
MAOB P27338 2/20 0.45
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP1B1 Q16678 1/20 0.42
ERN1 O75460 1/20 0.42
MAPT P10636 3/20 0.42
RECQL P46063 2/20 0.42
PLIN1 O60240 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569619 1.00 PTGS2 (0.56) PTGS2NFE2L2NFKB1JUNHSD11B1
SCHEMBL1339824 0.86 PTGS2 (0.55) PTGS2NFKB1CES2CES1BCHE
SCHEMBL1339826 0.86 PTGS2 (0.55) PTGS2NFKB1CES2CES1BCHE
SCHEMBL27353753 0.85 PTGS2 (0.54) PTGS2NFE2L2CES2CES1BCHE
SCHEMBL3581316 0.83 NFE2L2 (0.62) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL3581314 0.83 NFE2L2 (0.62) NFE2L2NFKB1JUNHSD11B1TFEB
SCHEMBL6369895 0.80 PTGS2 (0.54) PTGS2CES2CES1BCHEMAOB
SCHEMBL21268010 0.80 PTGS2 (0.69) PTGS2NFKB1BCHEMAOBCYP1A2
SCHEMBL14930494 0.80 PTGS2 (0.54) PTGS2NFE2L2MAOBCYP1A2MAPT
SCHEMBL5429626 0.78 PTGS2 (0.48) PTGS2CES2CES1BCHEMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
WO-2008150899-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER AND INFLAMMATORY DISEASES EMORY UNIVERSITY (US) 2008-12-11 WO disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-7371766-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2008-05-13 US disclosed
US-20040176384-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY 2004-09-09 US disclosed
US-6664272-B2 Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue EMORY UNIVERSITY 2003-12-16 US disclosed
EP-1242379-A1 CURCUMIN ANALOGUES FOR TREATING CANCER Emory University (US) 2002-09-25 EP disclosed
WO-2001040188-A9 CURCUMIN ANALOGUES FOR TREATING CANCER UNIV EMORY (US) 2002-07-25 WO disclosed
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY 2002-02-14 US disclosed
WO-2001040188-A1 CURCUMIN ANALOGUES FOR TREATING CANCER EMORY UNIVERSITY (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176384-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties PGF, VEGFA, VHL PTGS2 12/4885NFE2L2 137/4885NFKB1 95/4885
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES PGF, VEGFA, VHL PTGS2 12/4885NFE2L2 137/4885NFKB1 95/4885
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties PGF, VEGFA, VHL PTGS2 12/4885NFE2L2 137/4885NFKB1 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.